Cargando…

Prevalence of ERG expression and PTEN loss in a Brazilian prostate cancer cohort

PTEN is the most commonly inactivated tumor suppressor gene in primary prostate cancer (PCa) and its loss is associated with poor clinical outcomes. ERG rearrangement is a genomic alteration frequently found in PCa and its prognostic significance has yielded mixed results. Although the association o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morais, C.E., Gurgel, D.C., Teixeira, A.C., Mattos, T.V. Arruda, da Silva, A.V. Alves, Tavora, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Associação Brasileira de Divulgação Científica 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903141/ https://www.ncbi.nlm.nih.gov/pubmed/31826177 http://dx.doi.org/10.1590/1414-431X20198483

Ejemplares similares

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers
por: Rescigno, Pasquale, et al.
Publicado: (2018)

Novel Dual Color Immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma
por: Bhalla, Ritu, et al.
Publicado: (2013)

Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers
por: Burdelski, Christoph, et al.
Publicado: (2015)

Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion
por: Gumuskaya, Berrak, et al.
Publicado: (2013)

Correlations of PTEN and ERG Immunoexpression in Prostate Carcinoma and Lesions Related to Its Natural History: Clinical Perspectives
por: Voulgari, Olga, et al.
Publicado: (2023)

Cancer Prognosis Defined by the Combined Analysis of 8q, PTEN and ERG
por: Silva, Maria P., et al.
Publicado: (2016)

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer
por: Reid, A H M, et al.
Publicado: (2010)

Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer
por: NOH, BYEONG-JOO, et al.
Publicado: (2016)

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification
por: Furusato, B, et al.
Publicado: (2010)

Is PTEN loss associated with clinical outcome measures in human prostate cancer?
por: McCall, P, et al.
Publicado: (2008)

Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer
por: Kim, Sung Han, et al.
Publicado: (2015)

ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression
por: Hernández-Llodrà, Silvia, et al.
Publicado: (2017)

Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients’ prognosis
por: Al Bashir, Samir, et al.
Publicado: (2014)

Impact TMPRSS2–ERG Molecular Subtype on Prostate Cancer Recurrence
por: Kobelyatskaya, Anastasiya A., et al.
Publicado: (2021)

Transcriptional landscape of PTEN loss in primary prostate cancer
por: Imada, Eddie Luidy, et al.
Publicado: (2021)

PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort
por: Lotan, Tamara L., et al.
Publicado: (2017)

PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer Cells
por: Chatterjee, Payel, et al.
Publicado: (2013)

Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients
por: Abdel-Hady, Ahmed, et al.
Publicado: (2017)

NFATc1 Promotes Prostate Tumorigenesis and Overcomes PTEN Loss-Induced Senescence
por: Manda, Kalyan R., et al.
Publicado: (2015)

ERG Induces Epigenetic Activation of Tudor Domain-Containing Protein 1 (TDRD1) in ERG Rearrangement-Positive Prostate Cancer
por: Kacprzyk, Lukasz A., et al.
Publicado: (2013)

Effect of PTEN loss on metabolic reprogramming in prostate cancer cells
por: Zhou, Xin, et al.
Publicado: (2019)

5′ UTR Control of Native ERG and of Tmprss2:ERG Variants Activity in Prostate Cancer
por: Zammarchi, Francesca, et al.
Publicado: (2013)

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
por: Punnoose, Elizabeth A, et al.
Publicado: (2015)

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer
por: Cuzick, J, et al.
Publicado: (2013)

β-Catenin Is Required for Prostate Development and Cooperates with Pten Loss to Drive Invasive Carcinoma
por: Francis, Jeffrey C., et al.
Publicado: (2013)

An Update on the Structure of hERG
por: Butler, Andrew, et al.
Publicado: (2020)

The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer
por: Wang, Shan, et al.
Publicado: (2016)

Emerging role of PTEN loss in evasion of the immune response to tumours
por: Vidotto, Thiago, et al.
Publicado: (2020)

A Case Presentation Emphasizing the Value of Full-field ERG in Retinal Dystrophies
por: CORICI, A.C, et al.
Publicado: (2015)

Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer
por: Thangapazham, Rajesh, et al.
Publicado: (2014)

PTEN Loss is Associated with Upgrading of Prostate Cancer from Biopsy to Radical Prostatectomy
por: Lotan, Tamara L., et al.
Publicado: (2014)

Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss
por: Bastos, Débora C, et al.
Publicado: (2020)

A Three-Marker FISH Panel Detects More Genetic Aberrations of AR, PTEN and TMPRSS2/ERG in Castration-Resistant or Metastatic Prostate Cancers than in Primary Prostate Tumors
por: Qu, Xiaoyu, et al.
Publicado: (2013)

Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors
por: Dubovenko, Alexey, et al.
Publicado: (2015)

Expression and ERG regulation of PIM kinases in prostate cancer
por: Eerola, Sini K., et al.
Publicado: (2021)

Transcriptome Profiling of Prostate Cancer, Considering Risk Groups and the TMPRSS2-ERG Molecular Subtype
por: Kobelyatskaya, Anastasiya A., et al.
Publicado: (2023)

The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion
por: Burdelski, Christoph, et al.
Publicado: (2015)

ERG induces taxane resistance in castration-resistant prostate cancer
por: Galletti, Giuseppe, et al.
Publicado: (2014)

Atg7 cooperates with Pten loss to drive prostate cancer tumor growth
por: Santanam, Urmila, et al.
Publicado: (2016)

PTEN loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profiles
por: Geybels, Milan S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jq7gfqogd8vvk77eqk00ka4r3h